Cargando…

Importance of Public-Private Mix Collaboration in Tuberculosis Control: It Is Also Valuable in Patients with Multidrug-Resistant Tuberculosis

Detalles Bibliográficos
Autor principal:	Kwon, Yong-Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Tuberculosis and Respiratory Diseases 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801806/ https://www.ncbi.nlm.nih.gov/pubmed/33272005 http://dx.doi.org/10.4046/trd.2020.0152

Ejemplares similares

Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Comparison of Pre- and Post-Public–Private Mix Periods
por: Kang, Yewon, et al.
Publicado: (2021)

Fluoroquinolone resistance in multidrug-resistant tuberculosis patients
por: Lee, Hyun-Woo, et al.
Publicado: (2019)

Collaborative public–private initiatives targeting multidrug-resistant tuberculosis (MDR-TB) supported by the Lilly MDR-TB Partnership: experiences in 2012–2016
por: Shelby, Peter W, et al.
Publicado: (2017)

Predictors of Treatment Success for Multidrug Resistant Tuberculosis
por: Park, Sang Won
Publicado: (2016)

Treatments of Multidrug-Resistant Tuberculosis: Light at the End of the Tunnel
por: Lange, Christoph, et al.
Publicado: (2022)

The dynamic of tuberculosis case finding in the era of the public–private mix strategy for tuberculosis control in Central Java, Indonesia
por: Reviono, Reviono, et al.
Publicado: (2017)

Treatment Outcome and Mortality among Patients with Multidrug-resistant Tuberculosis in Tuberculosis Hospitals of the Public Sector
por: Jeon, Doo Soo, et al.
Publicado: (2011)

Prevention of Multidrug-Resistant Tuberculosis in Close Contacts. Back to the Future?
por: Schluger, Neil W.
Publicado: (2020)

A systematic assessment of the concept and practice of public-private mix for tuberculosis care and control
por: Malmborg, Rasmus, et al.
Publicado: (2011)

Tuberculosis Surveillance and Monitoring under the National Public-Private Mix Tuberculosis Control Project in South Korea 2016–2017
por: Min, Jinsoo, et al.
Publicado: (2020)

A review of mobile health interventions for public private mix in tuberculosis care
por: Tumuhimbise, Wilson, et al.
Publicado: (2021)

Multidrug-resistant tuberculosis
por: Zager, Ellen M, et al.
Publicado: (2008)

Multidrug-resistant tuberculosis
por: Lemos, Antônio Carlos Moreira, et al.
Publicado: (2013)

Multidrug-resistant tuberculosis: diagnosis, checklists, adverse events, advice and outcomes
por: Bothamley, Graham H.
Publicado: (2022)

Quality Tuberculosis Care in Indonesia: Using Patient Pathway Analysis to Optimize Public–Private Collaboration
por: Surya, Asik, et al.
Publicado: (2017)

Multidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai
por: Udwadia, Zarir F., et al.
Publicado: (2014)

A survey to assess the extent of public-private mix DOTS in the management of tuberculosis in Zambia
por: Chongwe, Gershom, et al.
Publicado: (2015)

What’s Next for the Standard Short-Course Regimen for Treatment of Multidrug-Resistant Tuberculosis
por: Campbell, Jonathon R., et al.
Publicado: (2019)

Multidrug-resistant tuberculosis/rifampicin-resistant tuberculosis: Principles of management
por: Prasad, Rajendra, et al.
Publicado: (2018)

Pharmacotherapy for multidrug resistant tuberculosis
por: Chhabra, Naveen, et al.
Publicado: (2012)

The Threat of Multidrug-resistant Tuberculosis
por: Paul, Rudrajit
Publicado: (2018)

Fistulized multidrug-resistant tuberculosis
por: El Omri, Naoual, et al.
Publicado: (2017)

Scale and Ambition in the Engagement of Private Providers for Tuberculosis Care and Prevention
por: Wells, William A.
Publicado: (2019)

Public–Private Mix Models of Tuberculosis Care in Pakistan: A High-Burden Country Perspective
por: Ullah, Waseem, et al.
Publicado: (2021)

The value of effective public tuberculosis treatment: an analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia
por: Miller, Thaddeus L, et al.
Publicado: (2013)

Multidrug-resistant Tuberculosis Lymphadenitis as the Initial Presentation of Secondary Multidrug-resistant Tuberculosis: A Case Report
por: Ogundipe, Temitayo, et al.
Publicado: (2018)

Undetected Multidrug-Resistant Tuberculosis Amplified by First-line Therapy in Mixed Infection
por: Hingley-Wilson, Suzanne M., et al.
Publicado: (2013)

Impact of Molecular Drug Susceptibility Testing on the Time to Multidrug-resistant Tuberculosis Treatment Initiation
por: Jeon, Doosoo, et al.
Publicado: (2020)

Rapid diagnosis and shorter regimen for multidrug-resistant tuberculosis: A priority to improve treatment outcome
por: Prasad, Rajendra, et al.
Publicado: (2017)

An Innovative Public–Private Mix Model for Improving Tuberculosis Care in Vietnam: How Well Are We Doing?
por: Do Thu, Thuong, et al.
Publicado: (2020)

Multidrug-resistant Tuberculosis Detection, Latvia
por: Skenders, Girts, et al.
Publicado: (2005)

Multidrug-resistant Tuberculosis in Central Asia
por: Cox, Helen Suzanne, et al.
Publicado: (2004)

Multidrug-resistant Tuberculosis in Military Recruits
por: Freier, Grace, et al.
Publicado: (2006)

Characteristics of multidrug-resistant tuberculosis in Namibia
por: Ricks, Philip M, et al.
Publicado: (2012)

Unusual Complication of Multidrug Resistant Tuberculosis
por: Sharma, Prerna, et al.
Publicado: (2017)

Nomogram to predict multidrug-resistant tuberculosis
por: Wang, Saibin, et al.
Publicado: (2020)

Diagnosis and treatment of multidrug-resistant tuberculosis
por: Jang, Jong Geol, et al.
Publicado: (2020)

Scrofula Caused by Multidrug-Resistant Tuberculosis
por: Pedro, Bárbara, et al.
Publicado: (2020)

Multidrug-resistant tuberculosis in Sierra Leone
por: Lakoh, Sulaiman, et al.
Publicado: (2022)

Public and/or private health care: Tuberculosis patients' perspectives in Myanmar
por: Saw, Saw, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ldj84ufgja3hf960924n1idfo0